OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
Sara Cacciapuoti, Luca Potestio, Gianluca Guerrasio, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 2637-2644
Open Access | Times Cited: 7
Sara Cacciapuoti, Luca Potestio, Gianluca Guerrasio, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 2637-2644
Open Access | Times Cited: 7
Showing 7 citing articles:
JAK Inhibitors in Psoriatic Disease
Matteo Megna, Luca Potestio, Angelo Ruggiero, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 3129-3145
Open Access | Times Cited: 15
Matteo Megna, Luca Potestio, Angelo Ruggiero, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 3129-3145
Open Access | Times Cited: 15
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study
Matteo Megna, Angelo Ruggiero, Fabrizio Martora, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 9, pp. 2691-2691
Open Access | Times Cited: 4
Matteo Megna, Angelo Ruggiero, Fabrizio Martora, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 9, pp. 2691-2691
Open Access | Times Cited: 4
Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study
Luca Potestio, Fabrizio Martora, Flavia Raia, et al.
Dermatology and Therapy (2025)
Open Access
Luca Potestio, Fabrizio Martora, Flavia Raia, et al.
Dermatology and Therapy (2025)
Open Access
Biomarker discovery in psoriatic disease
Darshini Ganatra, Vinod Chandran
Current Opinion in Rheumatology (2025)
Closed Access
Darshini Ganatra, Vinod Chandran
Current Opinion in Rheumatology (2025)
Closed Access
Brodalumab for Plaque Psoriasis in the Canadian Real-World Setting: A Retrospective Cohort Analysis of up to 4 Years
V. Gaudet, Irina Turchin, Charles Lynde, et al.
Dermatology and Therapy (2025)
Open Access
V. Gaudet, Irina Turchin, Charles Lynde, et al.
Dermatology and Therapy (2025)
Open Access
Janus kinase inhibitors for psoriatic arthritis: Evidence from a systematic review and network meta-analysis
Sotirios G. Tsiogkas, Arriana Gkouvi, Katerina‐Maria Kontouli, et al.
Autoimmunity Reviews (2025), pp. 103819-103819
Open Access
Sotirios G. Tsiogkas, Arriana Gkouvi, Katerina‐Maria Kontouli, et al.
Autoimmunity Reviews (2025), pp. 103819-103819
Open Access
Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry
Martina Kojanová, Barbora Turková, Spyridon Gkalpakiotis, et al.
Advances in Therapy (2024) Vol. 41, Iss. 10, pp. 3951-3971
Open Access | Times Cited: 2
Martina Kojanová, Barbora Turková, Spyridon Gkalpakiotis, et al.
Advances in Therapy (2024) Vol. 41, Iss. 10, pp. 3951-3971
Open Access | Times Cited: 2
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 6, pp. 677-685
Closed Access | Times Cited: 1
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 6, pp. 677-685
Closed Access | Times Cited: 1
